Golimumab

Introduction Overview

Generic Name

golimumab

Brand Name

Simponi, Simponi Aria, Simponi SmartJect

Dosage Form

intravenous solution, subcutaneous solution

Drug Class

TNF alfa inhibitors

Pharmacokinetics

Absorption:
Golimumab is administered either via subcutaneous injection or intravenous infusion. When given subcutaneously, golimumab is absorbed slowly with peak serum concentrations typically observed within 2 to 6 days post-dose. Bioavailability following subcutaneous administration is approximately 53%, which reflects incomplete absorption characteristic of monoclonal antibodies administered via this route. The slow absorption phase supports the dosing intervals ranging from every 2 to 4 weeks for subcutaneous injections. The intravenous route bypasses absorption processes, delivering golimumab directly into systemic circulation, resulting in immediate availability.

Distribution:
Golimumab, like other monoclonal antibodies, is primarily distributed within the vascular and interstitial spaces. It exhibits a relatively small volume of distribution approximating plasma volume due to its large molecular size and hydrophilic nature. Tissue penetration is generally limited but sufficient to reach sites of inflammation where TNF-alpha is expressed. Golimumab binds to its target tumor necrosis factor alpha (TNFα) with high affinity, and this binding may influence distribution at sites of active inflammation. Binding to cell receptors may act as a sink, potentially affecting apparent distribution kinetics.

Metabolism:
Golimumab is metabolized through the reticuloendothelial system similarly to endogenous immunoglobulin G (IgG). It is catabolized into small peptides and amino acids via ubiquitous proteolytic pathways and enzymatic degradation rather than hepatic cytochrome P450 metabolism. This characteristic reduces the likelihood of hepatic drug interactions and influences the pharmacokinetics favorably in patients with hepatic impairment.

Elimination:
The elimination half-life of golimumab ranges roughly between 14 and 20 days, allowing for monthly dosing intervals. Clearance occurs primarily through proteolytic catabolism by the reticuloendothelial system and target-mediated drug disposition. The presence of anti-drug antibodies can increase clearance and reduce drug exposure. Renal elimination is negligible due to the high molecular weight of the antibody. Steady-state concentrations are typically achieved after multiple dosing cycles. Clinical trials have shown relatively predictable elimination kinetics, facilitating consistent therapeutic dosing regimens.

Dosage Forms

Available Dosage Forms:
- Intravenous solution: 50 mg/4 mL (12.5 mg/mL) single-dose vial used for infusion.
- Subcutaneous solution: 100 mg/mL and 50 mg/0.5 mL pre-filled syringe or autoinjector (Simponi SmartJect).

Dosages for Adults and Adolescents:
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis: Subcutaneous injection of 50 mg once monthly is typical. Intravenous infusion (Simponi Aria) may be administered at 2 mg/kg every 8 weeks.
- Ulcerative Colitis: Initiation with 200 mg subcutaneous injection at week 0, followed by 100 mg at week 2, then maintenance dosing of 100 mg every 4 weeks.
- Polyarticular Juvenile Idiopathic Arthritis: Subcutaneous dosing 30 mg/m2 (not exceeding 50 mg) once monthly in children aged 2 years and older.

Specific Patient Populations:
- Pediatric patients aged 2 years and older: indicated for polyarticular juvenile idiopathic arthritis, dosing typically weight- or surface area-based with close clinical monitoring.
- Renal or hepatic impairment: no dose adjustment recommended owing to nonhepatic metabolism and minimal renal elimination.
- Elderly: Standard dosing applies, but close monitoring for infections is advised given increased vulnerability.
- Patients with active infections or history of tuberculosis: caution warranted; baseline screening and monitoring required per clinical guidelines.

Clinical guidelines emphasize rotating injection sites for subcutaneous administration to reduce local site reactions. Healthcare professionals administer intravenous infusions in controlled settings every 4 to 8 weeks to manage serious autoimmune conditions effectively.

Mechanism Of Action

Golimumab is a fully human monoclonal antibody that specifically binds to tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine implicated in the pathogenesis of multiple autoimmune diseases. By binding with high affinity and specificity, golimumab neutralizes both soluble and transmembrane forms of TNFα, preventing it from interacting with its receptors on cell surfaces. This inhibition blocks downstream signaling pathways involved in inflammatory and immune responses.

At the cellular level, TNFα binding to its receptors activates nuclear factor kappa B (NF-κB) and other transcription factors that induce expression of inflammatory mediators such as cytokines, chemokines, and adhesion molecules. Golimumab disrupts this cascade, leading to reduced leukocyte infiltration, suppression of endothelial activation, and decreased synovial inflammation in conditions like rheumatoid arthritis and psoriatic arthritis.

Biochemically, blocking TNFα reduces the production of interleukins (IL-1, IL-6), matrix metalloproteinases, and other mediators responsible for tissue destruction and joint damage. This mechanism also alleviates systemic features of inflammatory diseases, including fatigue and fever.

Clinically, golimumab’s inhibition of TNFα has been shown to reduce disease activity, inhibit structural joint damage progression, and improve physical function in patients with autoimmune disorders. Compared to other TNF inhibitors like adalimumab and infliximab, golimumab offers the convenience of monthly dosing and both subcutaneous and intravenous formulations, expanding therapeutic options. Clinical studies have demonstrated similar efficacy and safety profiles, affirming its place among TNF antagonists in therapeutic regimens.

Emerging research continues to explore golimumab’s impact on immune modulation and its potential applications in broader inflammatory conditions.

Pharmacological Actions

Selective inhibition of tumor necrosis factor alpha (TNFα), neutralizing its activity.
Suppression of pro-inflammatory cytokine cascade including interleukins and chemokines.
Reduction in leukocyte migration and infiltration into inflamed tissues.
Downregulation of endothelial adhesion molecule expression, reducing inflammation.
Inhibition of matrix metalloproteinase activity, protecting joint cartilage.
Improvement in immune-mediated inflammatory disease symptoms and signs.
Modulation of immune response leading to decreased autoimmunity.
Reduction of systemic inflammation markers such as C-reactive protein (CRP).
Alleviation of synovial membrane inflammation and pannus formation.
Stabilization of disease progression in rheumatoid arthritis and psoriatic arthritis.
Partial restoration of physical function and quality of life in chronic autoimmune diseases.
Potential immunosuppressive effects increasing susceptibility to infections.
Pharmacodynamic relationships with serum golimumab concentration and TNFα levels.
Dose-dependent therapeutic efficacy with safety mediated by selective targeting.
Mechanism consistent with other biologic TNF inhibitors used in autoimmune diseases.

Therapeutic Or Clinical Uses

Treatment of moderate to severe rheumatoid arthritis in adults.
Management of active psoriatic arthritis, alone or in combination with methotrexate.
Therapy for ankylosing spondylitis to reduce signs and symptoms.
Treatment of polyarticular juvenile idiopathic arthritis in children aged 2 years and above.
Management of moderate to severe ulcerative colitis in adult patients refractory to or intolerant of conventional therapies.
Use in patients who have failed or are intolerant to other TNF inhibitors due to its unique pharmacologic profile.
Reduction in structural joint damage progression in inflammatory arthritis.
Improvement of patient-reported physical function and disease activity scores.
Off-label use in other inflammatory conditions where TNFα plays a pathogenic role (under clinical discretion).
Adjunctive therapy to disease-modifying antirheumatic drugs (DMARDs) to enhance efficacy.
Potential to enable steroid-sparing strategies in chronic autoimmune disease management.
Treatment option for patients contraindicated for traditional immunosuppressive agents.
Management of chronic inflammation and prevention of complications related to autoimmune disorders.
Therapeutic alternative in patients with inadequate response to conventional therapies.
Allowed for monotherapy or combination therapy depending on disease severity and clinical judgment.

Side Or Adverse Effects

Increased risk of serious and opportunistic infections, including tuberculosis and fungal infections.
Injection site reactions such as pain, redness, itching, swelling, and bruising.
Upper respiratory tract infections presenting with symptoms like runny nose, sneezing, and sore throat.
Abnormal liver function tests suggestive of hepatotoxicity in some patients.
Elevated blood pressure (hypertension) occurrences during treatment.
Skin rash and other cutaneous hypersensitivity reactions.
Hematologic abnormalities including low blood cell counts: anemia, leukopenia, thrombocytopenia.
Rare cases of new or worsening heart failure or exacerbation of pre-existing congestive heart failure.
Development of autoantibodies and potential drug-induced lupus-like syndrome.
Neurological events such as numbness, tingling, weakness, or demyelinating disorders.
Allergic reactions ranging from mild hypersensitivity to severe anaphylaxis.
Possible reactivation or exacerbation of latent viral infections like hepatitis B.
Gastrointestinal symptoms including abdominal pain, diarrhea, and dyspepsia.
Rare reports of malignancies including lymphoma and other cancers potentially linked to immunosuppression.
Potential worsening or new onset of psoriasis in some patients.

Precautions

Screen patients for latent tuberculosis prior to initiation; treat if positive before starting golimumab.
Avoid use in patients with active infections or chronic infections due to immunosuppressive effects.
Closely monitor for signs and symptoms of infection during and after therapy.
Exercise caution in patients with history of demyelinating disorders or nerve-muscle diseases such as multiple sclerosis or Guillain-Barré syndrome.
Monitor liver function regularly due to risk of hepatotoxicity.
Take particular care in patients with congestive heart failure; monitor for worsening symptoms.
Evaluate hematologic parameters periodically given potential for cytopenias.
Avoid live vaccines during treatment and for a specified period afterward due to risk of infection.
Use pregnancy category considerations; counsel females of childbearing potential and monitor pregnancy closely.
Inform breastfeeding patients of the potential unknown effects and advise accordingly.
Rotate injection sites to minimize local adverse effects for subcutaneous administration.
Educate patients about signs of infection and when to seek urgent medical care.
Delay or avoid golimumab administration in patients with recent exposure to severe infections.
Assess cancer risk history before initiation, especially lymphoma or other malignancies.
Discuss potential risks and benefits with patients and caregivers, emphasizing vigilance.

Warnings

High risk of serious, potentially fatal infections including tuberculosis, bacterial sepsis, invasive fungal infections, and opportunistic pathogens.
Potential for reactivation of latent tuberculosis and hepatitis B virus requiring screening and monitoring.
Use is contraindicated in patients with active infections or chronic infections until resolved.
Increased risk of malignancies including lymphoma reported in patients treated with TNF inhibitors.
Possible exacerbation or new onset of heart failure; monitor patients closely and discontinue if worsens.
Risk of serious hypersensitivity reactions including anaphylaxis and angioedema.
Neurologic events including demyelinating disease and seizures have been reported.
Avoid live vaccines during and for at least several months after treatment due to immunosuppression.
May cause hematologic abnormalities such as pancytopenia, aplastic anemia, and thrombocytopenia.
Use caution in patients with psoriasis; paradoxical worsening or new onset may occur.
Pregnancy risk is undetermined; healthcare providers should weigh benefits versus risks.
Potential for immunogenicity leading to decreased efficacy or adverse effects.
Risk of developing lupus-like syndrome, which may require discontinuation of therapy.
Withdrawal or interruption of therapy can lead to disease flare; manage carefully.
Need for ongoing vigilance in monitoring for rare but serious adverse events.

Contraindication

Known hypersensitivity to golimumab or any component of the formulation, including rubber or latex components of the autoinjector.
Active serious infections such as tuberculosis, sepsis, or opportunistic infections.
Congestive heart failure classified as New York Heart Association (NYHA) class III or IV.
Concurrent use with other biologic TNF inhibitors or potent immunosuppressants without medical supervision.
Patients with active malignancy unless benefit outweighs risk, based on clinical judgment.
History of demyelinating disease such as multiple sclerosis without careful evaluation.
Live vaccines administration concurrent with golimumab therapy.
Known hypersensitivity to murine proteins or previous severe allergic reactions to monoclonal antibodies.
Patients with untreated latent tuberculosis or hepatitis B infection.
Severe uncontrolled infections including abscesses or chronic infections.
Pregnancy unless clinically justified; insufficient data for widespread use.
Use in infants under 2 years of age due to lack of safety and efficacy data.
Combination with anakinra or abatacept, as increased risk of infections and adverse reactions reported.
Patients with history of Guillain-Barré syndrome.
Inadequately monitored patients with hematological disorders or neutropenia.

Drug Interactions

Concomitant use with other TNF inhibitors such as etanercept, adalimumab, certolizumab, or infliximab increases risk of infections and adverse effects; generally avoided.
Abatacept use with golimumab can potentiate immunosuppression and risk of infections.
Anakinra (IL-1 receptor antagonist) co-administration should be avoided due to increased risk of neutropenia and infections.
Rituximab and golimumab may enhance immunosuppressive effects increasing infection risk.
Tocilizumab, an IL-6 receptor antagonist, combined with golimumab can exacerbate immunosuppression.
Live vaccines contraindicated during and for several months post-treatment due to immunosuppression.
Potential interaction with methotrexate: while often used concomitantly, monitoring for additive toxicity is warranted.
No significant interaction with cytochrome P450 substrates due to monoclonal antibody metabolism.
Use with caution with live attenuated vaccines due to impaired immune response.
Herbal supplements with immunomodulatory properties may cause additive effects and should be disclosed.
Antibiotics are generally safe but monitor for superinfections in immunocompromised states.
No interaction with common analgesics and NSAIDs but monitor for infection masking.
Vaccination efficacy may be reduced during golimumab therapy; timing of immunizations should be planned accordingly.
Corticosteroids may be used concomitantly but increase overall infection risk.
Drug interaction profile necessitates full medication review to avoid additive immunosuppression.

Preparations Of The Drug

Simponi Autoinjector: subcutaneous solution containing 100 mg/mL and 50 mg/0.5 mL prefilled autoinjectors.
Simponi Pre-Filled Syringe: subcutaneous solution available as 100 mg/mL and 50 mg/0.5 mL for manual injection.
Simponi Aria Single-Dose Vial: intravenous solution available as 50 mg/4 mL (12.5 mg/mL) for infusion.
Simponi SmartJect: an autoinjector device designed to facilitate self-administration of subcutaneous golimumab.
The intravenous formulation is preservative-free and intended for dilution and infusion under medical supervision.
All preparations are supplied refrigerated and must be protected from light prior to use.
Prefilled syringes contain latex in the needle cap requiring caution in latex-allergic patients.
Storage requires refrigeration at 2°C to 8°C; do not freeze or shake vigorously.
Subcutaneous formulations are single-use and should be discarded after one administration.
Visual inspection required before use; do not use if solution is cloudy or contains particulates.
Patient education materials provided with self-injectable preparations for proper handling and administration.
Packaging includes safety needles to prevent accidental needle-stick injuries.
Documentation and lot tracking important due to biological nature of the drug.
Alternative biosimilar preparations may be available depending on regulatory approvals.
Preparation for infusion involves dilution in sterile saline per prescribing information and administration over approximately 30 minutes.